A further analysis in these studies confirmed that the overexpression of PD-L2 in myeloid blasts and the monocyte-restricted increase in PDL-1 expression with therapy are the most important causes of inactivity related to PDL-1 inhibitors in patients with AML [44,46]. The gene discussed is CD274; the disease is acute myeloid leukemia.